Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

60
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
60

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Safety of Rituximab in Pemphigus Foliaceus: A Systematic Review and Meta-analysis.

Dermatology and therapy·2026
Same author

Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS).

European journal of cancer (Oxford, England : 1990)·2026
Same author

Comment on 'Incidence and Mortality of Mucous Membrane Pemphigoid in France': reply from authors.

The British journal of dermatology·2026
Same author

Predicting Age-Related Facial Hyperpigmentation via Dermatologist Knowledge Elicitation and Generative Modeling.

Dermatology and therapy·2026
Same author

PD-1 and TIGIT coexpression enables selective enrichment of clonally expanded tumor-reactive CD8 T cells for melanoma TIL therapy.

Journal of translational medicine·2026
Same author

Daratumumab as a therapeutic option for rituximab-recalcitrant pemphigus.

The Journal of investigative dermatology·2026

Related Experiment Video

Updated: May 29, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.8K

Optimizing Pemphigus Management With Rituximab and Short-Term Relapse Predictors.

Vivien Hébert1, Sami Hamwi1, Emmanuelle Tancrède-Bohin2

  • 1Department of Dermatology, Centre Hospitalier Universitaire de Rouen and Institut National de la Santé et de la Recherche Médicale (INSERM) U1234, Normandie University, Rouen, France.

JAMA Dermatology
|February 5, 2025
PubMed
Summary

An additional rituximab infusion at 6 months can reduce pemphigus relapse rates in patients with predictors of relapse. This preemptive treatment strategy shows promise for maintaining complete remission and minimizing corticosteroid use.

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.6K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.0K

Related Experiment Videos

Last Updated: May 29, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.8K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.6K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.0K

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Rituximab is approved for moderate to severe pemphigus.
  • A significant percentage of patients relapse within a year of standard rituximab treatment.

Purpose of the Study:

  • To evaluate the efficacy of an additional rituximab infusion at 6 months in pemphigus patients achieving complete remission (CR) but exhibiting relapse predictors.
  • To assess the impact on CR rates, relapse rates, and safety.

Main Methods:

  • A multicenter cohort study involving 87 newly diagnosed pemphigus patients treated with the RITUX 3 regimen.
  • Patients in CR at 6 months with relapse predictors (high PDAI, elevated anti-DSG1/DSG3 antibodies) received an additional rituximab infusion.
  • Outcomes measured included CR without corticosteroids at 12 months, relapse rates, and safety.

Main Results:

  • Of 77 patients in CR at 6 months, 30 received an additional rituximab infusion due to relapse predictors.
  • The overall relapse rate was 2.6%, with only 2 patients relapsing.
  • At 12 months, 93.5% of patients who achieved CR at 6 months maintained CR without corticosteroids.

Conclusions:

  • Preemptive rituximab treatment guided by relapse predictors (PDAI, anti-DSG1/DSG3 antibodies) can significantly reduce short-term relapse rates in pemphigus patients.
  • This strategy may improve long-term disease control and reduce the need for corticosteroids.